Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.60 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085954 | 0.89 | SCD (0.65) | SCDSCD5RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL165005 | 0.88 | SCD (0.55) | SCDSCD5HSD11B1HSP90AA1HSP90AB1 | |
| SCHEMBL12459923 | 0.86 | HSD11B1 (0.50) | SCDHSD11B1ROCK2HSD17B10 | |
| SCHEMBL13212081 | 0.86 | ROCK2 (0.55) | SCDHSD11B1ROCK2HSD17B10 | |
| SCHEMBL8596155 | 0.85 | PARP14 (0.62) | SCDSCD5HSD11B1RIPK1HSP90AA1 | |
| SCHEMBL19226714 | 0.83 | KMT2A (0.53) | SCDHSD11B1ROCK2HSD17B10 | |
| SCHEMBL17886737 | 0.83 | ROCK2 (0.49) | SCDHSD11B1RIPK1ROCK2HSD17B10 | |
| SCHEMBL17888325 | 0.83 | HSD11B1 (0.53) | SCDHSD11B1RIPK1ROCK2HSD17B10 | |
| SCHEMBL169074 | 0.82 | ROCK2 (0.58) | SCDHSD11B1HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL3218965 | 0.80 | SCD (0.52) | SCDSCD5ROCK2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| WO-2015032286-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SCD 4693/4885SCD5 4044/4885HSD11B1 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.